Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 10/20 | 0.58 |
| ▸ | OPRM1 | P35372 | 4/20 | 0.58 |
| ▸ | ACE | P12821 | 1/20 | 0.57 |
| ▸ | XIAP | P98170 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29376540 | 0.97 | OPRD1 (0.61) | OPRD1OPRM1 | |
| SCHEMBL29462069 | 0.92 | OPRD1 (0.65) | OPRD1OPRM1 | |
| SCHEMBL29509580 | 0.91 | OPRD1 (0.59) | OPRD1OPRM1 | |
| Trifluoroacetic Acid SCHEMBL28184395 | 0.89 | OPRD1 (0.52) | OPRD1OPRM1ACEXIAP | |
| Trifluoroacetic Acid SCHEMBL29706375 | 0.89 | OPRD1 (0.52) | OPRD1OPRM1ACEXIAP | |
| SCHEMBL5611736 | 0.86 | OPRD1 (0.55) | OPRD1OPRM1 | |
| SCHEMBL5058350 | 0.86 | OPRD1 (0.55) | OPRD1OPRM1 | |
| SCHEMBL30444236 | 0.83 | SLC6A2 (0.62) | OPRD1OPRM1 | |
| SCHEMBL21581709 | 0.82 | OPRM1 (0.58) | OPRD1OPRM1 | |
| SCHEMBL26454172 | 0.82 | OPRM1 (0.58) | OPRD1OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4612135-A1 | ORAL PHARMACEUTICAL FORMULATIONS CONTAINING 4-((2-HYDROXY-3-METHOXYBENZYL)AMINO) BENZENESULFONAMIDE DERIVATIVES | Veralox Therapeutics Inc. (US) | 2025-09-10 | — | — | EP | claimed |
| WO-2024097846-A1 | ORAL PHARMACEUTICAL FORMULATIONS CONTAINING 4-((2-HYDROXY-3-METHOXYBENZYL)AMINO) BENZENESULFONAMIDE DERIVATIVES | VERALOX THERAPEUTICS (US) | 2024-05-10 | — | — | WO | claimed |
| EP-3054936-B1 | 4-((2-HYDROXY-3-METHOXYBENZYL)AMINO) BENZENESULFONAMIDE DERIVATIVES AS 12-LIPOXYGENASE INHIBITORS | EASTERN VIRGINIA MEDICAL SCHOOL (US) | 2023-10-18 | — | — | EP | claimed |
| EP-4731206-A2 | COMPOSITIONS AND METHODS OF USE TO TREAT 12-LIPOXYGENASE (12-LOX) MEDIATED DISEASES | Veralox Therapeutics Inc. (US) | 2026-04-29 | — | — | EP | disclosed |
| US-20260048071-A1 | 12-LIPOXYGENASE INHIBITORS FOR THE TREATMENT OF LUPUS | Cadrenal Therapeutics, Inc. | 2026-02-19 | — | — | US | disclosed |
| US-20260022375-A1 | METHODS AND COMPOSITIONS FOR SELECTIVELY MODULATING GENE EXPRESSION IN MEGAKARYOCYTES AND PLATELETS | UNIV JEFFERSON (US) | 2026-01-22 | — | — | US | disclosed |
| US-12441790-B2 | Binding proteins to the human thrombin receptor, PAR4 | MONASH UNIVERSITY (AU) | 2025-10-14 | — | — | US | disclosed |
| EP-4615432-A2 | 12-LIPOXYGENASE INHIBITORS FOR THE TREATMENT OF LUPUS | Veralox Therapeutics Inc. (US) | 2025-09-17 | — | — | EP | disclosed |
| EP-4612135-A1 | ORAL PHARMACEUTICAL FORMULATIONS CONTAINING 4-((2-HYDROXY-3-METHOXYBENZYL)AMINO) BENZENESULFONAMIDE DERIVATIVES | Veralox Therapeutics Inc. (US) | 2025-09-10 | — | — | EP | disclosed |
| EP-4558635-A2 | METHODS AND COMPOSITIONS FOR SELECTIVELY MODULATING GENE EXPRESSION IN MEGAKARYOCYTES AND PLATELETS | Thomas Jefferson University (US) | 2025-05-28 | — | — | EP | disclosed |
| US-20250066345-A1 | COMPOSITIONS AND METHODS OF USE TO TREAT 12-LIPOXYGENASE (12-LOX) MEDIATED DISEASES | Cadrenal Therapeutics, Inc. | 2025-02-27 | — | — | US | disclosed |
| WO-2022236086-A1 | COMPOUNDS FOR MODULATING PLATELET-TYPE 12-(S)-LIPOXYGENASE AND METHODS OF USE FOR SAME | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-11-10 | — | — | WO | disclosed |
| US-20220347113-A1 | PEPTIDES AND METHODS OF TREATING SEPSIS, ATHEROSCLEROSIS, THROMBOSIS, STROKE, HEART ATTACK AND INFLAMMATION | UNIV ILLINOIS (US) | 2022-11-03 | — | — | US | disclosed |
| CN-111094300-B | Benzo-heteroaryl derivative, preparation method and application thereof in medicine | 江苏恒瑞医药股份有限公司 | 2022-09-16 | — | — | CN | disclosed |
| EP-4055032-A1 | PEPTIDES AND METHODS OF TREATING SEPSIS, ATHEROSCLEROSIS, THROMBOSIS, STROKE, HEART ATTACK AND INFLAMMATION | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2022-09-14 | — | — | EP | disclosed |
| CN-112074521-B | Compounds as protease activated receptor 4(PAR4) inhibitors for the treatment of platelet aggregation | 深圳信立泰药业股份有限公司 | 2022-08-09 | — | — | CN | disclosed |
| CN-112074523-B | Compounds as protease activated receptor 4(PAR4) inhibitors for the treatment of platelet aggregation | 深圳信立泰药业股份有限公司 | 2022-08-09 | — | — | CN | disclosed |
| WO-2022087058-A1 | COMPOSITIONS AND METHODS FOR TREATING CARDIOVASCULAR RELATED DISORDERS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2022-04-28 | — | — | WO | disclosed |
| US-11293064-B2 | Human miRNAs for use in diagnosis, prognosis, and therapy of human conditions and diseases | THOMAS JEFFERSON UNIVERSITY (US) | 2022-04-05 | — | — | US | disclosed |
| US-11274077-B2 | 4-((2-hydroxy-3-methoxybenzyl)amino)benzenesulfonamide derivatives as potent and selective inhibitors of 12-lipoxygenase | EASTERN VIRGINIA MEDICAL SCHOOL (US) | 2022-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11274077-B2 | 4-((2-hydroxy-3-methoxybenzyl)amino)benzenesulfonamide derivatives as potent and selective inhibitors of 12-lipoxygenase | ALOX12, ALOX15, ALOX15B | OPRD1 819/4885OPRM1 657/4885ACE 3888/4885 |
| US-20260048071-A1 | 12-LIPOXYGENASE INHIBITORS FOR THE TREATMENT OF LUPUS | ALOX12, ALOX5, ALOX15 | OPRD1 817/4885OPRM1 774/4885ACE 844/4885 |
| US-20260022375-A1 | METHODS AND COMPOSITIONS FOR SELECTIVELY MODULATING GENE EXPRESSION IN MEGAKARYOCYTES AND PLATELETS | MPL, MCL1, MATK | OPRD1 3754/4885OPRM1 2929/4885ACE 4838/4885 |
| US-20250066345-A1 | COMPOSITIONS AND METHODS OF USE TO TREAT 12-LIPOXYGENASE (12-LOX) MEDIATED DISEASES | ALOX12, LOX, ALOX15 | OPRD1 2108/4885OPRM1 971/4885ACE 1208/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.